Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 23, Issue 2, Pages 254-266Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.09.112
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA 82578, P01 CA 77839, P01 CA 10645 1] Funding Source: Medline
- NIDDK NIH HHS [R01 DK 62112, R37 DK 47297] Funding Source: Medline
- PHS HHS [R01 89578] Funding Source: Medline
Ask authors/readers for more resources
Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available